1. Home
  2. TVTX vs MTRN Comparison

TVTX vs MTRN Comparison

Compare TVTX & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

SELL

Current Price

$48.93

Market Cap

4.7B

Sector

Health Care

ML Signal

SELL

Logo Materion Corporation

MTRN

Materion Corporation

HOLD

Current Price

$176.42

Market Cap

4.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
MTRN
Founded
N/A
1931
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.6B
IPO Year
2013
2000

Fundamental Metrics

Financial Performance
Metric
TVTX
MTRN
Price
$48.93
$176.42
Analyst Decision
Strong Buy
Buy
Analyst Count
15
5
Target Price
$75.14
★ $303.75
AVG Volume (30 Days)
★ 2.3M
200.0K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
★ 0.31%
EPS Growth
92.89
★ 1178.57
EPS
N/A
★ 4.57
Revenue
N/A
N/A
Revenue This Year
$55.24
$33.41
Revenue Next Year
$43.78
$9.16
P/E Ratio
★ N/A
$67.85
Revenue Growth
N/A
N/A
52 Week Low
$22.59
$110.69
52 Week High
$68.73
$324.99

Technical Indicators

Market Signals
Indicator
TVTX
MTRN
Relative Strength Index (RSI) 47.24 30.66
Support Level $49.46 $164.03
Resistance Level $59.93 $260.28
Average True Range (ATR) 2.67 14.99
MACD 0.37 -4.36
Stochastic Oscillator 76.14 14.90

Price Performance

Historical Comparison
TVTX
MTRN

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About MTRN Materion Corporation

Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.

Share on Social Networks: